Who we are

AndzonBio2 translates leading academic research into novel neuroinflammation therapies through innovative mechanisms, disciplined development, and partnership-driven execution.

The company currently advances two programs targeting:

STING
(Stimulator of Interferon Genes)

A central regulator of innate immune activations, interferon signaling and neuroinflammation pathways.

ACSL4
(Acyl-CoA Synthetase Long Chain Family Member 4)

an enzyme involved in lipid metabolism and ferroptosis pathways with emerging roles in neuroinflammation and neurodegeneration.

Both mechanisms present compelling opportunities to intervene upstream of neuronal dysfunction and disease progression across multiple CNS indications.

Our Pipeline

Our Team

Experienced leadership team with track record in neuroscience,
drug development, venture creation, and strategic partnerships.

Loic Lhuillier, PhD

Acting CEO and Co-founder

LLoic is a seasoned professional with over 20 years of experience in strategic, operational, and scientific leadership in the life sciences industry. His expertise spans new healthcare technology evaluation, venture creation, preclinical and clinical program leadership, investment portfolio oversight across different therapeutic areas, and fundraising.

Loic held pivotal roles in biotech and research organizations. As Chief Scientific Officer at AndzonBio1, he led project evaluations for cardiovascular, renal, and metabolic indications, selecting and shaping discovery plans for its programs. At Exonate Ltd, where he served as Chief Operating Officer, he oversaw all R&D delivery in multiple therapeutic areas, including a Phase 1b trial for diabetic eye disease, while contributing to securing funding from Janssen Pharma and the Wellcome Trust.

He co-founded a Cambridge (UK)-based company focused on neurodegenerative diseases and managed a multi-peptide immunotherapy project for type 1 diabetes at King’s College London, raising funding and advancing it through preclinical and clinical stages, including licensing to a European corporate partner.

Earlier positions include Programme Manager for Precision Medicine at InnovateUK, where he managed a £200 million portfolio, created a Precision Medicine Roadmap, and developed funding competitions for vaccine development and global epidemics.

His foundational roles involved managing discovery biology at Lectus Therapeutics for chronic pain, and Novartis on allosteric modulators for mood disorders.

He studied neuroscience in Paris, France and holds a PhD in Molecular and Cellular Biology (neurobiology) from the University of Houston.

Simon Loiodice, PhD

Chief Operating Officer

Simon has a PhD in neuropsychopharmacology with a strong entrepreneurial and business-driven mindset. He has 15 years of experience (gained in pharma, CRO and biotech) in early drug development with a primary focus on neuroscience. He also has significant experience in operational and strategic leadership as well as a track record in implementing and leading research collaborations with academic groups and biotech/pharma companies in the CNS space.

Simon previously founded and led 2 CNS biotech companies and is a biotech entrepreneur since 2020. Throughout his entrepreneurial journey, he gained significant experience in company building/structuring, project search & evaluation, deal making/negotiation and business development.

Prior to his entrepreneurial experiences, Simon worked 5 years (2016-2021) in a CRO as Head of CNS Pharmacology and was involved in multiple CNS drug development programs with leading European and US-based biotech/pharma. Before that, Simon notably had positions at UCB Pharma and Sanofi where he gained pharma experience in nonclinical pharmacology / drug safety evaluation.

Throughout his career, Simon has designed and executed multiple CNS drug development programs and led multiple translational neuroscience projects. His work notably resulted in various 1^st author publications which were co-authored with leaders in the field.

Mounia Azzi, PhD

Chief Business Development

Mounia is a Life Sciences Executive with over 20 years of experience at the interface of research, industry and early-stage investment.

Mounia studied Neuroscience in France then moved to Canada to pursue postdoctoral research at the University of Montreal where she later became a research associate. After, she transitioned to industry, joining Bellus Health (formerly Neurochem) as head of the cell biology group.

In 2009, she entered the world of life sciences investment as Investment Manager at MSBi Valorisation, before joining CQDM as Program Director where she helped structure major collaborative R&D initiatives.

In 2012, she contributed to the launch and growth of the NEOMED Institute as Director of Scientific Affairs and then of Nexelis (ex NEOMED-LABS), where she served successively as Vice President of Corporate Development and Chief Business Officer.

In 2019, she joined adMare BioInnovations as Vice President of Program Development and Partnerships before becoming Vice President Corporate Development, leading strategic partnerships, government relations, communications, and the development of emerging biotech ventures.

John Christopher, PhD

Project Lead, MedChem

John has more than 25 years industrial medicinal chemistry and project leadership experience in multiple therapeutic areas including CNS, inflammatory, respiratory, oncology and anti-viral and has led drug discovery campaigns across a diverse range of protein target classes.

He has held senior positions in large pharmaceutical (GlaxoWellcome, GSK) and biotech companies (Heptares, Sosei Heptares, Sitala Bio), leading projects in the hit discovery, hit to lead, lead optimisation and early preclinical development stages. John has significant experience managing external resources in the CRO sector and collaborating with partnered biotech and pharmaceutical companies. Most recently John was Head of Chemistry at Sitala
Bio, and prior to that he was a Director of Medicinal Chemistry at Heptares Therapeutics / Sosei Heptares (now known as Nxera Pharma). John is currently a Drug Discovery consultant, providing strategic Medicinal Chemistry and Project Leadership input to several European and UK based biotech companies.

After graduating with a first-class BSc (Hons) in Chemistry with Bioorganic Chemistry (University of Birmingham) John gained a PhD in Synthetic Organic Chemistry (Glasgow University) and is a Fellow of the Royal Society of Chemistry, Chartered Chemist and Chartered Scientist. John is the author or inventor on more than 75 manuscripts, reviews, book chapters and patents.